The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
|Videos|November 10, 2020
James Grotta, MD: The Impact of COVID-19 on Stroke Care
Author(s)James Grotta, MD
The vascular neurologist at Memorial Hermann Medical Group discusses how stroke care has been affected throughout the COVID-19 pandemic.
Advertisement
"COVID-19 has been a pretty big stress for them. Just like many other spheres in our economy and society that have taken a hit, it remains to be seen what impact it will have on these first responders.”
The coronavirus disease 2019 (COVID-19) pandemic has created concern around stroke care on 2 fronts: an elevated risk for stroke associated with the virus coupled with fear of seeking care for stroke in hospital settings due to potential virus exposure. Both of these have had a substantial impact beyond the patient, with a considerable toll evident among emergency medical services (EMS) providers and those working in the critical care setting.
With timeliness being a pillar of care in stroke, it is very troubling to see the long-term effects of the pandemic, including clinician burnout and a dwindling EMS pool,
In an interview with NeurologyLive, James Grotta, MD, a vascular neurologist at Memorial Hermann Medical Group, provides context on some of the major ways that the virus has impacted stroke care.
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.
The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.
GV101 receives FDA fast track designation for the treatment of Friedreich ataxia, with a phase 2 trial planned to begin enrollment in late 2026.
In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
GV101 Gains FDA Fast Track Status for Friedreich Ataxia Ahead of Phase 2 Trial
3
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
4
Headlining Current Advances and Challenges in Multiple Sclerosis Care
5